**Core tip:** In this study, we retrospectively assessed the usefulness of *en bloc* right hemicolectomy with pancreaticoduodenectomy (RHCPD) in five patients with locally advanced right-sided colon cancer (LARCC) with malignant infiltration into adjacent organs. A histological examination confirmed malignant infiltration into the duodenum and/or pancreas in four patients, with no malignant infiltration into the superior mesenteric vein. The OS rates were 80% at 1 year and 60% at 5 years. All patients with node-negative status survived more than seven years without recurrence. The long-term survival is possible for patients, particularly node-negative ones, with LARCC if the RHCPD is performed successfully.

INTRODUCTION
============

Locally advanced colorectal cancers invading into adjacent organs account for 5.5%-16.7% of all colorectal cancers\[[@B1]-[@B3]\]. Incomplete resection and separation of colon cancer from adherent organs are considered to lead to tumor recurrence and a poor prognosis\[[@B4],[@B5]\]. Locally advanced right-sided colon cancer (LARCC) can invade the duodenum, pancreas, and other organs, and in this situation, *en bloc* right hemicolectomy with pancreaticoduodenectomy (RHCPD) is necessary to achieve R0 resection.

RHCPD for LARCC was first reported in 1953\[[@B6]\], and high-volume centers, including our hospital, have reported acceptable outcomes with RHCPD\[[@B7]-[@B9]\]. However, the number of reports describing the long-term survival and histological findings is limited given the few cases of LARCC treated with RHCPD\[[@B7],[@B10],[@B11]\].

In the present study, we retrospectively reviewed the preoperative and intraoperative assessments of LARCC with malignant infiltration into adjacent organs and the clinical outcomes of RHCPD in these cases.

MATERIALS AND METHODS
=====================

Patient characteristics
-----------------------

We retrospectively reviewed the database of Saitama Medical Center, Jichi Medical University, between January 2009 and December 2016. During this period, 299 patients underwent radical right hemicolectomy (RHC) for right-sided colon cancer. Among them, 5 patients underwent RHCPD because of LARCC with direct infiltration to the duodenum and/or pancreas. Preoperative computed tomography (CT) was routinely performed to evaluate local tumor infiltration into adjacent organs. The preoperative carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA19-9) levels were routinely tested in all patients. Preoperative upper endoscopy, colonoscopy, and histological confirmation of the diagnosis were performed in all patients. The optimal treatment strategies for LARCC were discussed in a multidiscipline forum including surgeons, oncologists and radiologists.

Indications for RHCPD
---------------------

The indications for RHCPD were as follows: (1) histological confirmation of colon cancer; (2) colon cancer that could not be dissociated from the pancreas and/or duodenum because of tumor infiltration; (3) radical resection deemed feasible on preoperative imaging and intraoperative exploration; and (4) no secondary or recurrent tumors.

Surgical method of RHCPD
------------------------

After the Cattell-Braasch maneuver, a Kocher maneuver was performed to fully mobilize the duodenum. We evaluated the resectability of the LARCC and the amount of infiltration into the duodenum and/or pancreas without dissecting the adherent organs from the cancer. After confirming that radical resection was feasible and could lead to R0 resection, we performed RHCPD.

First, RHC was performed in accordance with the standard procedure. Pancreaticoduodenectomy (PD) was then performed *via* the standard procedure, and if the superior mesenteric vein (SMV) was involved, we performed *en bloc* SMV resection and end-to-end anastomosis of the SMV. Reconstruction was carried out in accordance with the modified Child's reconstruction method. End-to-side anastomosis was made between the proximal stump of the pancreas and jejunum. The stent of the pancreatic duct was routinely used in pancreatojejunostomy. Finally, reconstruction of the bowel was performed *via* stapled side-to-side anastomosis of the ileum and transverse colon. After reconstruction, rubber drains were placed near the biliary and pancreatic anastomoses, and the abdominal wall wounds were closed.

Primary and secondary outcomes
------------------------------

The overall survival (OS) was considered the primary outcome. The disease-free survival (DFS), 30-d postoperative mortality, and major complications were considered the secondary outcomes. The staging process was based on the tumor-lymph node-metastasis (TNM) classification proposed by the American Joint Committee of Cancer\[[@B12]\]. Postoperative pancreatic fistula were categorized according to the International Study Group on Pancreatic Fistula Definition (ISGPFD)\[[@B13]\].

Observation indices
-------------------

Clinical data were carefully reviewed. Demographic variables, intraoperative data, and postoperative parameters were recorded. Numerical data were presented as the median (range).

Follow-up system
----------------

All patients were examined at three-month intervals at our outpatient department. The patients were followed up in accordance with the standard protocol, including CEA and CA19-9 measurement, abdominal ultrasound or CT, and annual colonoscopy.

Ethical issues
--------------

The study design and procedures were approved by the Ethics Committee of Saitama Medical Center, Jichi Medical University.

RESULTS
=======

The characteristics of the patients in this series are shown in Table [1](#T1){ref-type="table"}. Between 2009 and 2016, five patients (two male and three female) underwent RHCPD for LARCC with direct infiltration into adjacent organs in our hospital. The median age of the patients was 70 years (range, 47-74 years). The tumors were located in the ascending colon (three patients) and transverse colon (two patients). The histological results confirmed the diagnosis of right-sided colon cancer in all of the patients. The preoperative CEA values were 12.3 ng/mL (range, 0.5-120.8 ng/mL) and CA19-9 values were 22.5 IU/mL (range, 13.7-196.8 IU/mL). None of the patients received preoperative chemotherapy. Preoperative CT revealed infiltration of the tumor into the duodenum in all patients, the pancreas in four patients (Cases 2-5), and the SMV in two patients (Cases 4 and 5). Distant metastasis was not observed on preoperative imaging assessment in four patients (Cases 1-4). Although tumor thrombosis in the SMV was noted in one patient (Case 5), we were unable to administer preoperative chemotherapy because of tumor bleeding and stenosis (Figure [1](#F1){ref-type="fig"}).

###### 

Patients' characteristics

  **Case**   **Gender**   **Age (yr)**   **Site of colon cancer**   **Adjacent organ infiltration on preoperative CT**   **Preoperative CEA (ng/mL)**   **Preoperative CA19-9 (IU/mL)**
  ---------- ------------ -------------- -------------------------- ---------------------------------------------------- ------------------------------ ---------------------------------
  1          Female       73             T                          Du                                                   120.8                          22.5
  2          Female       74             A                          Du + Pa + St                                         36.6                           20.3
  3          Male         70             A                          Du + Pa                                              0.5                            49.2
  4          Female       57             T                          Du + Pa + Gb + SMV                                   2.6                            13.7
  5          Male         47             A                          Du + Pa + SMV[1](#T1FN1){ref-type="table-fn"}        12.3                           196.8

Tumor thrombosis in SMV. A: Ascending colon; T: Transverse colon; CEA: Carcinoembryonic antigen; CA19-9: Cancer antigen 19-9; CT: Computed tomography; Du: Duodenum; St: Stomach; Pa: Pancreas; Gb: Gallbladder; SMV: Superior mesenteric vein.

![Preoperative computed tomography showing tumor thrombosis in the superior mesenteric vein in Case 5. T: Tumor; TT: Tumor thrombosis; PV: Portal vein; SPV: Splenic vein; SMV: Superior mesenteric vein; J1V: First jejunal vein; J2V: Second jejunal vein.](WJGO-9-372-g001){#F1}

The perioperative data of the patients are listed in Table [2](#T2){ref-type="table"}. Because infiltration of the tumor into the SMV was suspected based on preoperative CT findings or surgical exploration, we performed RHCPD plus SMV resection in three patients (Cases 2, 4 and 5) and added removal of tumor thrombosis in one patient (Case 5). In one patient (Case 1), we added distal pancreatectomy to RHCPD because of a neuroendocrine tumor in the pancreatic tail. The median operative time was 506 minutes (range, 304-538 minutes), and the median operative blood loss was 940 mL (range, 200-2760 mL). Major postoperative complications occurred in 3 patients (60%) as pancreatic fistula (grade B and grade C, according to ISGPFD) and delayed gastric empty (DGE). After the operation, the postoperative hospital stay was 35 d (range, 27-39 d). The postoperative course was fair in all patients, and none of the patients died during their hospital stay.

###### 

Surgical findings and complications

  **Case**   **Operation**     **Adjacent organ infiltration in surgical exploration**   **OT (min)**   **OBL (mL)**   **DHS (d)**   **Complications**
  ---------- ----------------- --------------------------------------------------------- -------------- -------------- ------------- -------------------
  1          PD + RHC + DP     Du                                                        406            940            35            PF (B)
  2          PD + RHC + SMVR   Du + Pa + St + SMV                                        524            840            27            PF (C)
  3          PD + RHC          Du + Pa + Gb                                              304            200            33            PF (A), DGE
  4          PD + RHC + SMVR   Du + Pa + Gb + SMV                                        538            2760           36            PF (A)
  5          PD + RHC + SMVR   Du + Pa + SMV[1](#T2FN1){ref-type="table-fn"}             506            2470           39            PF (A)

Tumor thrombosis in SMV. OT: Operation time; OBL: Operative blood loss; DHS: Duration of hospital stay; PD: Pancreaticoduodenectomy; RHC: Right hemicolectomy; DP: Distal pancreatectomy; SMVR: Superior mesenteric vein resection; Du: Duodenum; St: Stomach; Pa: Pancreas; Gb: Gallbladder; SMV: Superior mesenteric vein; PF: Pancreatic fistula; DGE: Delayed gastric emptying.

The histological characteristics are listed in Table [3](#T3){ref-type="table"}. According to the TNM classification, stage T~4b~N~0~M~0~ (Cases 3 and 4), stage T~4b~N~0~M~1a~ (Case 1, with metastasis of peripancreatic lymph node), stage T~4b~N~1b~M~1b~ (Case 2, with metastasis of periduodenal lymph node and tumor thrombosis in SMV), and stage T~4b~N~1a~M~1a~ (Case 5, with tumor thrombosis in SMV) were defined. A histological examination confirmed direct infiltration into the duodenum and/or pancreas head in four patients. Even though direct infiltration into the SMV was suspected by preoperative CT in two patients (Cases 4 and 5) or by surgical exploration in three patients (Cases 2, 4 and 5), no malignant infiltration into the SMV was confirmed. However, two patients (Cases 2 and 5) were histologically confirmed to have tumor thrombosis in the SMV (Figure [2](#F2){ref-type="fig"}). Well-differentiated adenocarcinoma (Cases 3, 4 and 5), moderately differentiated adenocarcinoma (Case 1), and mucinous adenocarcinoma (Case 2) were confirmed histologically. All of the tumors had clear resection margins (R0).

![Histological findings revealing tumor thrombosis in the superior mesenteric vein in Case 2 (× 4). SMV: Superior mesenteric vein; TT: Tumor thrombosis.](WJGO-9-372-g002){#F2}

###### 

Histological findings

  **Case**   **Stage**   **Histological infiltration**   **Histological type**                                                           **R**                 
  ---------- ----------- ------------------------------- ------------------------------------------------------------------------------- --------- ----------- ---
  1          4b          0                               1a (LYM[1](#T3FN1){ref-type="table-fn"})                                        Du        Mod + NET   0
  2          4b          1b                              1b (LYM[2](#T3FN2){ref-type="table-fn"}, OTH[3](#T3FN3){ref-type="table-fn"})   St        Muc         0
  3          4b          0                               0                                                                               Du + Pa   Well        0
  4          4b          0                               0                                                                               Du + Gb   Well        0
  5          4b          1a                              1a (OTH[3](#T3FN3){ref-type="table-fn"})                                        Du + Pa   Well        0

Extra-regional lymph node metastasis (peripancreatic lymph node);

Extra-regional lymph node metastasis (periduodenal lymph node);

Tumor thrombosis in SMV. Mod: Moderately differentiated adenocarcinoma; Well: Well-differentiated adenocarcinoma; NET: Neuroendocrine tumor; Du: Duodenum; St: Stomach; Pa: Pancreas; Gb: Gallbladder.

The chemotherapy regimens and outcomes are listed in Table [4](#T4){ref-type="table"}. One patient received adjuvant chemotherapy with capecitabine treatment (Case 1). Two patients did not wish to receive adjuvant chemotherapy (Cases 3 and 4). One patient could not receive adjuvant chemotherapy because of appetite loss, but we introduced chemotherapy with cetuximab treatment for liver metastasis (Case 2). One patient had early recurrence with liver metastasis, and we introduced chemotherapy with capecitabine plus oxaliplatin and bevacizumab treatment (Case 5). The median follow-up time was 77 mo (range, 11-95 mo). No patients were lost to follow-up. During this period, two patients with tumor thrombosis died from liver metastasis (Cases 2 and 5). The OS rates were 80% at 1 year and 60% at 5 years. Three patients survived more than six years with no recurrence (Cases 1, 3 and 4). All patients without lymph node metastasis survived more than seven years (Cases 3 and 4). On the other hand, only one patient with lymph node metastasis achieved a long-term survival (Case 1).

###### 

Chemotherapy and outcomes

  **Case**   **ACT**   **DFS (mo)**   **CT**             **OS (mo)**   **Status**   **CD**
  ---------- --------- -------------- ------------------ ------------- ------------ --------
  1          Cape      77             \-                 77            Alive        
  2          \-        5              Cetu               11            Dead         LM
  3          \-        95             \-                 95            Alive        
  4          \-        85             \-                 85            Alive        
  5          \-        1              Cape + OX + Beva   11            Dead         LM

ACT: Adjuvant chemotherapy; CT: Chemotherapy; DFS: Disease-free survival; OS: Overall survival; CD: Cause of death; LM: Liver metastasis; Cape: Capecitabine; Cetu: Cetuximab; Beva: Bevacizumab; OX: Oxaliplatin.

DISCUSSION
==========

To distinguish between inflammatory adhesion and malignant infiltration is difficult by preoperative imaging assessments or surgical exploration. With the development of CT technology, preoperative CT provides accurate information about the staging of colon cancer and invasion beyond the muscularis propria into adjacent organs\[[@B14]\]. However, preoperative CT and surgical exploration often cannot distinguish inflammatory adhesions from malignant infiltration\[[@B10],[@B11],[@B15]-[@B18]\]. In our series, malignant infiltration to the duodenum was suspected in all 5 cases by preoperative CT and surgical exploration and subsequently confirmed in 4 cases (80%) by a histological examination. However, malignant infiltration into the pancreas was suspected in 4 cases by preoperative CT and surgical exploration but only confirmed in 2 cases (50%) by a histological examination. Furthermore, malignant infiltration into the SMV was suspected in 2 cases by preoperative CT and 3 cases by surgical exploration but not confirmed in any cases (0%) by a histological examination. Therefore, in our series, both preoperative CT and surgical exploration were found to be unreliable for identifying malignant infiltration, and this phenomenon is in line with the findings of previous studies.

In the right-sided colon cancer, the rate of malignant infiltration in adhesion between the cancer and adjacent organs has been reported to range from 71%-94%\[[@B7],[@B10],[@B11],[@B19]\]. In addition, separation of colon cancer from the adherent organs may lead to tumor recurrence rates of 90%-100%\[[@B4],[@B5]\]. Therefore, adhesion between the colon cancer and adjacent organs should be assumed to be malignant infiltration. When LARCC is suspected of having infiltrated the adjacent organs, RHCPD should be performed as long as radical operation is possible. While a few authors maintain that SMV invasion is not an indication for RHCPD\[[@B20],[@B21]\], we advise against hesitating to perform RHCPD with SMV resection to achieve R0 resection\[[@B8],[@B22]\].

Previous studies have reported that *en bloc* multivisceral resection can lead to a good prognosis, with a 5-year survival rate ranging from 21%-55%, for patients with LARCC invading adjacent organs\[[@B7],[@B10],[@B11],[@B20]\]. In our series, all patients underwent RHCPD, and three additionally underwent SMV resection to achieve R0 resection. In all patients, R0 resection was achieved, and the OS rate at 5 years was favorable (60%). Interestingly, the patients with node-negative status survived for more than seven years without recurrence (Cases 3 and 4). Saiura et al\[[@B7]\] reported that patients with node-negative status achieved a significantly longer survival than node-positive patients. Similarly, in another study, the patients that survived for more than seven years all had node-negative status\[[@B10]\].

Some colorectal cancers may behave in a locally aggressive invasion instead of causing lymphatic or hematogenous spread\[[@B7],[@B11],[@B23],[@B24]\]. As such, RHCPD seems to provide a favorable survival for LARCC patients with this condition. In our series, only one patient (Case 1) with node-positive status survived for more than six years without recurrence, and this patient received adjuvant chemotherapy with capecitabine. Even if a patient has node-positive status, *en bloc* multivisceral resection plus adjuvant chemotherapy might be able to improve their prognosis. In our series, all patients with node-negative status had well-differentiated adenocarcinoma (Cases 3 and 4). Furthermore, the patient with mucinous adenocarcinoma had node-positive status in not only the regional lymph nodes but also the periduodenal lymph nodes (Case 2). In a previous report, the rate of lymph node metastasis was significantly lower for well-differentiated adenocarcinoma than mucinous or poorly differentiated adenocarcinoma in LARCC with direct infiltration into adjacent organs\[[@B7]\]. These previous results and our findings suggest that the histological type of tumor may affect the lymph node metastasis and prognosis in patients with LARCC.

In our series, two patients with tumor thrombosis in SMV relapsed with liver metastasis soon after operation (Cases 2 and 5). A previous review of colorectal cancer with venous tumor thrombosis found that the incidence of synchronous liver metastasis was as high as 19.5%, and the incidence of liver metastatic recurrence after complete surgical resection of the tumor was as high as 24.4%, while the liver metastatic recurrence rate of general colorectal cancer was 7.1%\[[@B25]\]. Tumor thrombosis in the SMV therefore seems to be a strong risk factor of synchronous and metachronous liver metastasis, leading to a poor prognosis. In the FOxTROT trial, preoperative chemotherapy resulted in significant higher rates of downstaging (55%) and R0 resection (96%) than postoperative chemotherapy for locally advanced colon cancer\[[@B26]\]. In another previous study, preoperative chemotherapy achieved a tumor volume reduction (62.5% of volume), R0 resection (100%), and an encouraging prognosis (3- to 5-year DFS of 88.9%-85.6% and OS of 95.3%) for locally advanced colon cancer\[[@B27]\]. Given the findings of these recent reports, it may thus be better to perform preoperative chemotherapy for LARCC patients with tumor thrombosis in the SMV than preemptive surgery. The role of induction preoperative chemotherapy, which might be indicated in T4b colon cancer, has not been discussed in previous reports of LARCC. In the era of advanced chemotherapy for colorectal cancer, preoperative chemotherapy might result in a better prognosis for LARCC patients with severe invasion, lymph node metastasis, or tumor thrombosis in the SMV. This issue merits further studies in the near future.

Several limitations associated with the present study warrant mention. First, the number of patients in this study was small. Because cases of LARCC undergoing RHCPD are rare, the number of patients per medical institution tends to be small. Large-scale studies may produce more reliable results. Second, the chemotherapy regimens varied among patients. In this era of advanced chemotherapy, administering the same regimen for a long-term study seems unfeasible. However, the present study also has several strengths. First, all of the patients were followed up, and the assessment of the prognosis proved to be accurate. Second, a histological examination was performed in detail, and we were able to evaluate the relationship between the preoperative CT findings, surgical exploration, and prognosis and histological findings.

In conclusion, we found that a long-term survival was therefore possible for patients with LARCC infiltrating adjacent organs, provided that RHCPD was successfully performed. This aggressive approach may help improve the prognosis, particularly in patients with node-negative status. Large-scale and long-term studies may produce more reliable results.

COMMENTS
========

Background
----------

In locally advanced colorectal cancers invading the adjacent organs, incomplete resection and the separation of colon cancer from any adherent organs are considered to lead to tumor recurrence and a poor prognosis. The number of reports describing the long-term survival and histological findings is limited given the few cases of locally advanced right-sided colon cancer (LARCC) treated by *en bloc* right hemicolectomy with pancreaticoduodenectomy (RHCPD).

Research frontiers
------------------

This is a retrospective single center experience regarding the long-term survival and histological findings of LARCC treated with RHCPD.

Innovations and breakthroughs
-----------------------------

Long-term survival was possible for patients with LARCC that had successfully undergone RHCPD. RHCPD may help improve the prognosis of patients with LARCC, particularly in patients with a node-negative status.

Applications
------------

The present study suggests that LARCC patients with a node-negative status are indicated for RHCPD. If a patient has tumor thrombosis in SMV, then the possibility of early recurrence should also be considered.

Peer-review
-----------

This manuscript deals with RHCPD for LARCC. The authors have described the preoperative assessment, intraoperative assessment, histological findings and prognosis.
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